Literature DB >> 6518776

General concepts for use of markers in clinical trials.

L Gordis.   

Abstract

Both indirect and direct methods have been widely employed for measuring medication compliance. Indirect methods include therapeutic or preventive outcome, assessment by the physician, interview with the patient, whether or not the prescription was filled, and a count of remaining pills. In many situations, direct methods may be feasible, including measurement of blood or serum levels or testing urine for excretion of the medication itself, a metabolic by-product, or a marker or tracer that has been added to the medication for detection purposes. For example, detection of penicillin or of salicylates can be used in measuring compliance, while in other circumstances, it may be necessary to add a detectable label to the medication. Ideally, such a marker should be nontoxic and pharmacologically and chemically inert [Porter AM: Br Med J 1:218-222, 1969]. The marker should be unaffected by physical and chemical properties of the urine, such as pH and temperature, quickly and freely excreted, and noncumulative. A simple, sensitive, and specific detection method should be available, and the marker should be such that the patient is unaware that it has been added. In direct measures of compliance, it is necessary to consider pharmacokinetic variations among individuals in absorption, distribution, metabolism, and excretion of drugs. In addition, temporal aspects of the sampling scheme assume great importance. Finally, the definition of compliance and noncompliance for a given study in relation to the specific question being tested in the investigation, as well as in regard to use of the marker itself, is an important issue for consideration.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6518776     DOI: 10.1016/0197-2456(84)90008-4

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  3 in total

1.  A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteers.

Authors:  E Hardy; S Kumar; S Peaker; M Feely; T Pullar
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

Review 2.  Role of patient compliance in clinical pharmacokinetics. A review of recent research.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  How should we measure medication adherence in clinical trials and practice?

Authors:  Jeannie K Lee; Karen A Grace; Terri G Foster; Monica J Crawley; Goldina I Erowele; Hazel J Sun; Phuong T Turner; Lance E Sullenberger; Allen J Taylor
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.